Log In
Print this Print this


Also known as: formerly LAX-202

  Manage Alerts
Collapse Summary General Information
Company MultiCell Technologies Inc.
DescriptionCombination of lofepramine and L-phenylalanine.
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase II
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat primary multiple sclerosis fatigue (PMSF)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today